The fecal immunochemical test (FIT) is commonly used for colorectal cancer (CRC) screening. Despite demographic variations in stool hemoglobin concentrations, few data exist regarding optimal positivity thresholds by age and sex.
C
olorectal cancer (CRC) is the second leading cause of cancer death in the United States (1) . In randomized trials, screening with guaiac-based fecal occult blood tests reduced CRC mortality by 15% to 33% (2, 3) . The fecal immunochemical test (FIT) has several advantages over guaiac-based tests, including greater specificity for human hemoglobin, the need for only 1 fecal sample, and no requirement for dietary or medication restrictions (1, 4) .
Quantitative FITs directly measure human hemoglobin concentrations in the stool. The quantitative threshold for a positive FIT result (positivity threshold) can be tailored to different settings and patient groups to optimize cancer detection (sensitivity) while limiting the number of colonoscopies triggered by positive FIT results. Population-based screening programs worldwide use a broad range of FIT positivity thresholds, ranging from 10 to 47 μg of hemoglobin per gram of stool (5) , although 20 μg/g is the convention in the United States (6) . Few studies have compared positivity thresholds of screening programs in large, diverse populations (7, 8) . Furthermore, fecal hemoglobin concentrations differ among population groups, with reports of higher concentrations in men than women and increasing levels with age (9 -11). Likewise, CRC incidence is higher in men than women and increases with age (12) . In contrast, women have a higher incidence of proximal (right-sided) cancer, which may be more difficult to detect by screening (13, 14) . Therefore, using the same FIT positivity threshold across subgroups may be suboptimal (15) . Previous studies examining positivity thresholds were limited by an insufficient number of cancer diagnoses to define the sensitivity of FIT, particularly in demographic subgroups (4, 7, 14, 16 -18) ; were conducted with population samples that did not resemble the general U.S. population (19) ; used outdated or qualitative tests (4) ; or lacked the comprehensive follow-up of negative FIT results that was needed to identify missed CRC (that is, false-negative results) (20, 21) .
We examined FIT performance measures in 2 large community-based screening programs using FIT outreach mailers with linkage to comprehensive cancer registries. We assessed the balance between cancer detection and screening burden at varying FIT positiv-ity thresholds. Our goal was to quantify the programmatic sensitivity of FIT (over several rounds of testing), as well as the potential effect of various positivity thresholds on a screening program, in a cohort representing a community-based, diverse population.
METHODS

Study Setting
This retrospective cohort study included members of Kaiser Permanente Northern California (KPNC) and Southern California (KPSC) who completed FIT screening between 1 January 2013 and 31 December 2014. The KPNC and KPSC integrated health care systems have approximately 8 million members who receive care in 40 medical centers. These systems provide comprehensive care, an integrated electronic health record, and cancer registries reporting to the SEER (Surveillance, Epidemiology, and End Results) program of the National Cancer Institute (NCI). Their diverse membership closely approximates the adult census population of California, except at the extremes of income (22) (23) (24) . The study was approved by the institutional review boards of KPNC and KPSC and conducted within the NCI-funded PROSPR II (Population-based Research to Optimize the Screening Process) consortium, which conducts multisite, coordinated, transdisciplinary research to evaluate and improve cancer screening processes.
FITs
The FIT-based CRC screening outreach programs at KPNC and KPSC began between 2006 and 2008 (8, 25) . Members aged 50 to 75 years who did not have a colonoscopy within 10 years or a sigmoidoscopy within 5 years were mailed a FIT kit annually. The kit included a 1-sample FIT (OC FIT-CHEK [Polymedco]), a standardized letter, directions for completing the test, and a preprinted laboratory requisition form. Patients mailed their completed FIT to a regional laboratory, where it was analyzed by using an OC-Sensor Diana automated system (Polymedco), with a positivity threshold greater than 20 μg/g (corresponding to 100 ng of hemoglobin per milliliter of test buffer) (26) . A result at the threshold was classified as negative. Patients with positive results were referred for colonoscopy. Patients and providers were informed whether the result was "positive" or "negative" but were not provided with the actual quantitative values. Results with a value greater than 200 μg/g were read as "overassay" and reported as positive.
Overall Cohort Eligibility Criteria and Follow-up
Patients were eligible to participate if they had a quantitative FIT result available between 1 January 2013 and 31 December 2014, regardless of whether it was their first-ever FIT; were 50 to 75 years of age; were at average risk for CRC (no personal history of CRC, total colectomy, or inflammatory bowel disease); and had been members of the health system for at least 2 years before the test result date (to capture previous endoscopy examinations or FITs). Participants were followed for 2 years after the test result date, or until their CRC diagnosis date if it was within 2 years. For details on cohort selection, see the Appendix Figure (available at Annals.org).
Data Sources
Quantitative FIT values were obtained directly from the automated OC-Sensor Diana machine. Patient characteristics (date of birth, sex, body mass index, race, and Hispanic ethnicity) were obtained from the electronic health record. The number of primary care visits and Charlson Comorbidity Index scores were computed with a standardized algorithm using International Classification of Diseases, Ninth Revision, codes from care episodes in the calendar year before the baseline FIT (27) . Colorectal adenocarcinoma diagnoses were obtained from the KPNC and KPSC cancer registries, which capture more than 99% of cancer diagnoses among members compared with manual review, and included the cancer site, morphology, and stage. Cancer was diagnosed in 1 of 3 ways: colonoscopy to follow up on a positive FIT result; colonoscopy or radiologic imaging after a negative FIT result because the patient had symptoms or laboratory abnormalities (such as anemia); or colonoscopy after a negative FIT result because the patient elected to continue future screening with an elective colonoscopy after the FIT. We considered only adenocarcinomas, which represent approximately 90% to 95% of all CRC cases, because these tumors are believed to follow the adenoma-carcinoma sequence and are potentially preventable through screening (28, 29) . Cancer location was defined as the right colon (proximal to the splenic flexure), left colon, or rectum. Advanced-stage cancer was defined as stage III (regional lymph node involvement) or stage IV (distant metastasis) according to the American Joint Committee on Cancer staging system, or as code 3 (disease in the regional lymph nodes), code 4 (regional disease with direct extension and spread to regional lymph nodes), or code 7 (distant metastasis) according to SEER Program Coding and Staging Manual 2013 (30) .
Statistical Analysis
The distribution of baseline quantitative FIT values among participants with and without CRC during follow-up, by age and sex, was summarized by using percentiles. The primary analysis examined the programmatic sensitivity, specificity, and corresponding CIs at FIT positivity thresholds of 10, 15, 20, 25, and 30 μg/g. Programmatic sensitivity was the proportion of patients with a CRC diagnosis within 2 years of FIT screening who had a quantitative FIT result above a given positivity threshold at baseline or during follow-up testing. Programmatic specificity was the proportion of patients without a CRC diagnosis whose quantitative FIT results were all at or below a given threshold. For each threshold, the number of cancer diagnoses and number of patients with a positive test result were determined and the number of participants with a positive result per cancer case detected was calculated. The same test characteristics were examined separately by age group (50 to 59, 60 to 69, and 70 to 75 years) and sex (male and female), with comparisons between subgroups made by using the 2 
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RESULTS
Overall Cohort Characteristics
Of 1 550 542 members who received a FIT, 1 212 461 (78%) completed at least 1 test in 2013 to 2014 (Figure 1) (Figure 1) . A total of 48 561 patients (7.6%) had a positive result at the conventional threshold of 20 μg/g, 36 906 (76%) of whom had a colonoscopy within 2 years of the baseline FIT (median, 33 days after receiving the result). The distributions of positive test results, colonoscopy follow-up, and cancer diagnoses were similar between those with quantitative results and the overall population of KPNC and KPSC members who had testing during the study period (data not shown).
Of 1245 cancer cases diagnosed at or within 2 years of the baseline FIT, 505 (41%) were in the right colon, 358 (29%) in the left colon, 362 (29%) in the rectum, and 20 (1.6%) of undefined primary location ( Table 1 ). The proportion of right-sided cancer cases increased with age (29% between 50 and 59 years, 44% between 60 and 69 years, and 53% between 70 and 75 years; P < 0.001) and was greater in women than men (46% vs. 36%; P = 0.004) (Appendix Tables 1 Influence of Varying FIT Positivity Thresholds on CRC Detection ORIGINAL RESEARCH available at Annals.org). Among those in whom cancer did not develop during follow-up, baseline stool hemoglobin values at the 95% percentile increased with age (13.4 μg/g for ages 50 to 59, 16.2 μg/g for ages 60 to 69, and 21.0 μg/g for ages 70 to 75 years; P < 0.001) and were higher in men than women (17.8 vs. 13.4 μg/g; P < 0.001) (Appendix Table 3 , available at Annals .org). For patients in whom cancer developed, median stool hemoglobin values from the baseline FIT were higher for left-sided than right-sided cancer or rectal cancer (60.0, 12.4, and 24.4 μg/g, respectively; P < 0.001 for each 2-way comparison) (Appendix Table 3 ).
FIT Performance at Varying Positivity Thresholds in the Overall Cohort
The proportion of cancer cases detected by FIT (programmatic sensitivity) decreased with higher positivity thresholds, from 987 of 1245 (79.3%) cases at 10 μg/g to 925 (74.3%) at 20 μg/g and 822 (66.0%) at 30 μg/g ( Table 2 ). The number of participants with a positive baseline or subsequent FIT result also decreased, from 84 293 at 10 μg/g (13.2% with a positive test result; programmatic specificity, 87.0%) to 48 561 at 20 μg/g (7.6% with a positive test result; specificity, 92.6%) and 35 017 at 30 μg/g (5.5% with a positive test result; specificity, 94.7%).
The number of positive test results per cancer case detected increased substantially at thresholds below 20 μg/g; it rose 11% from 25 to 20 μg/g (47 to 52 results), 22% from 20 to 15 μg/g (52 to 63 results), and 35% from 15 to 10 μg/g (63 to 85 results). Reducing the positivity threshold from 20 to 15 μg/g would have detected 25 additional cancer cases (3% increase) from 11 308 additional colonoscopies (23% increase), equating to 452 colonoscopies per additional cancer case detected.
FIT Performance at Varying Positivity Thresholds, Stratified by Age
Programmatic sensitivity and specificity decreased significantly with increasing age at thresholds between 10 and 30 μg/g. At 20 μg/g, the programmatic sensitivity decreased from 79.0% (95% CI, 74.8% to 82.7%) among those aged 50 to 59 years to 73.4% (CI, 69.4% to 77.1%) among those aged 60 to 69 years and 68.9% (CI, 63.2% to 74.3%) among those aged 70 to 75 years (P = 0.009) ( Table 3) . Programmatic specificity also declined with age, from 93.5% (CI, 93.4% to 93.6%) among those aged 50 to 59 years to 90.6% (CI, 90.4% to 90.8%) among those aged 70 to 75 years (P < 0.001), and the number of positive test results per cancer case detected decreased from 63 (57 to 70) to 40 (35 to 47).
FIT Performance at Varying Positivity Thresholds, Stratified by Sex
At all thresholds between 10 and 30 μg/g, FIT had lower programmatic sensitivity and higher programmatic specificity among women than men ( Table 3) . At 20 μg/g, the programmatic sensitivities were 77.0% (CI, 73.7% to 80.0%) and 70.6% (CI, 66.6% to 74.5%) for men and women, respectively (P = 0.011), and the programmatic specificities were 91.6% (CI, 91.5% to 91.7%) and 93.4% (CI, 93.3% to 93.5%) (P < 0.001). Decreasing the threshold from 20 to 10 μg/g led to substantial increases in the number of positive results per cancer case detected for both sexes, increasing 62% in men-from 47 (CI, 43 to 51) to 76 (CI, 70 to 83)-and 63% in women-from 60 (CI, 55 to 67) to 98 (CI, 89 to 108). Decreasing the threshold for women from 20 to 10 μg/g yielded a programmatic sensitivity similar to that of men at the 20-μg/g threshold, but with a lower programmatic specificity (88.2% vs. 91.6%) and more than double the number of positive results per cancer case detected (98 vs. 47).
Additional Analyses With 1-Year Follow-up
Similar patterns were seen for the tradeoff between sensitivity and specificity, both overall and among subgroups, when only 1 year of follow-up from the baseline FIT result was examined (Appendix and Appendix Tables 4 to 7, available at Annals.org). The sensitivity of Table 6 , available at Annals.org).
DISCUSSION
In this large, diverse, community-based sample of adults participating in FIT screening, programmatic sensitivity for CRC increased modestly with decreasing positivity thresholds, from 74.3% at 20 μg/g to 76.3% at 15 μg/g and 79.3% at 10 μg/g. The number of positive test results per cancer case detected over 2 years increased with decreasing positivity thresholds, especially those below 20 μg/g. The performance of FIT varied by age and sex, with lower programmatic sensitivity and specificity with increasing age and higher programmatic sensitivity and lower specificity in men than women.
The 5% increase in CRC programmatic sensitivity observed when the positivity threshold decreased from 20 μg/g to 10 μg/g is smaller than differences reported in some earlier studies (31), although previous reports were inconsistent and had small numbers of cancer cases, resulting in low precision (wide CIs) (32-34). A systematic review of several FIT brands found that a threshold lower than 20 μg/g yielded an overall sensitivity of 86% (CI, 75% to 92%), versus 63% (CI, 43% to 79%) for thresholds between 20 μg/g and 50 μg/g (4) . Previous studies with colonoscopy follow-up of all screening participants compared FIT sensitivity (using OC-Sensor Diana) for advanced adenomas at varying thresholds (32-35). They showed 5% to 10% increases in advanced adenoma sensitivity when the positivity threshold decreased from 20 μg/g to 10 μg/g. This increase is larger than what we observed for cancer cases and is clinically relevant, given that approximately 25% of advanced adenomas will progress to CRC within 10 years (36).
A few previous studies with colonoscopy follow-up suggested that FIT sensitivity for CRC and advanced adenomas is higher and its specificity lower in men than women (10, 34, 37), although reports conflicted and did not allow precise estimates by quantitative FIT thresholds (19) . Proposed explanations for this disparity include a higher proportion of harder-to-detect, right-sided cancer cases (34); lower serum hemoglobin concentrations (10); and longer colonic transit times in women than in men (38). Women in our cohort had a greater proportion of right-sided cancer than men, and women with cancer had lower mean stool hemoglobin concentrations than men with cancer (Appendix Table  3 ). In randomized trials of guaiac-based tests, women also had smaller relative reductions in CRC mortality than men (39). The apparent lower sensitivity of FIT in women is concerning, given that sigmoidoscopy also seems to be less effective in women (40). Few reports have been published on FIT performance trends by age, although FIT may perform better before age 50 than after (41), and worse after age 65 (42).
Our findings suggest that screening programs wishing to increase cancer detection by lowering their positivity threshold below the conventional 20 μg/g will require substantial additional colonoscopy and financial resources. The large increases in positive test results per cancer case detected are probably a result of the rarity of CRC in screening populations and the greater overlap in lower fecal hemoglobin concentrations between those with and without CRC. Some additional colonoscopies generated by positive test results without the presence of cancer (false-positive results in this study) would detect and remove advanced adenomas, probably reducing future cancer incidence (8, 31) . However, repeated annual testing can mean larger accumulated numbers of false-positive results; our 2-year programmatic specificity results were substantially lower than 1-time test specificity with 1-year follow-up (Appendix). The optimal positivity threshold (acceptable number of positive test results per cancer case detected) will depend on the availability of local colonoscopy resources. Lower-resourced settings may raise their positivity threshold, although in our study sensitivity at 30 μg/g declined from 74.3% to 66.0%. Of note, a screening program in the Netherlands increased its threshold from 15 μg/g to 47 μg/g after an unexpectedly high colonoscopy demand (43). The implications for screening programs of the observed differences in programmatic sensitivity and specificity by age and sex are less clear and probably depend on the relative importance given to colonoscopy burden or maximizing cancer detection across subgroups. As might be expected, given the lower baseline fecal hemoglobin concentrations in women, we observed a larger increase in programmatic sensitivity in women than men when the positivity threshold was decreased from 20 μg/g to 10 μg/g (7.1% vs. 3.5% increase). However, women also had a larger increase in positive test results per cancer case (38 vs. 29 more results), probably because of their lower cancer incidence rates. Lowering the positivity threshold for women may achieve a sensitivity similar to that in men and fewer interval cancer cases (34, 44), although others have proposed more aggressive screening in men because of their higher risk (12, 45, 46) . We are not aware of previous work advocating lower positivity thresholds in older age groups. Although FIT programmatic sensitivity and the number of positive test results per cancer case detected were lowest in those aged 70 to 75 years, both the risk for cancer and the risk for complications from colonoscopy increase with age (1).
Strengths of our study included a diverse, multicenter, community-based screening cohort, with quantitative FIT results available, including those from repeated testing; analyses from several laboratories; high overall screening rates, decreasing the potential for selection bias (47); high-quality cancer registries; more 
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Influence of Varying FIT Positivity Thresholds on CRC Detection cancer cases than in previous studies (7, 16 -18) ; and a U.S. screening population (19, 32) . Our study also had several potential limitations. First, we did not have quantitative FIT values available for all members who had FIT screening during the study interval. However, analyses by season and medical center did not reveal any pattern in missing quantitative values, and our positive predictive values were similar to those of previous publications reporting data from the entire population, including those without quantitative values (8, 48) . Second, we assumed that all cancer cases with quantitative values of 20 μg/g or greater would be detected if designated positive. Although follow-up colonoscopy rates and cancer registry ascertainment are high in the KPNC and KPSC screening programs (49) , imperfect follow-up would likely attenuate the benefit of lowering the positivity threshold. Third, despite cancer registry follow-up, estimates of programmatic sensitivity incorporate some differential verification bias: Patients with a FIT result greater than 20 μg/g were likely to receive immediate, invasive ascertainment sensitive for early-stage CRC (colonoscopy) rather than clinical follow-up with less sensitive ascertainment (cancer registry). Differential verification bias falsely increases sensitivity in studies of 1-time fecal-based cancer screening because of incomplete accrual of false-negative results (50) and could make the current threshold of 20 μg/g seem more advantageous. However, our primary results focus on the performance of a screening program over 2 years rather than a single FIT. Fourth, we could not measure false-negative results for advanced adenomas, thus our findings may reflect only part of the benefit of lower positivity thresholds. However, smaller studies have been able to estimate the effect of varying positivity thresholds on advanced adenoma detection using the same FIT brand (OC-Sensor Diana) (32) (33) (34) (35) . Fifth, because participants were followed for 2 calendar years and not precisely 2 rounds of screening, sufficient time may not have been allowed for colonoscopy follow-up of positive test results occurring toward the end of the 2-year follow-up. Finally, most participants had previous FIT screening, and if some of them had prevalent cancer removed, it may have increased the number of positive test results per cancer case detected as compared with populations screened for the first time (8) . However, as screening programs mature, measuring test performance in heterogeneous populations of firsttime and repeated screenees is important.
Among participants in a FIT-based screening program followed for 2 years from their baseline FIT, cancer detection and the number of positive test results per cancer case detected varied significantly and substantially by age and sex, suggesting that modifications in positivity thresholds by subgroups might optimize screening program performance, albeit with effects on the number of false-positive test results. Modifying the positivity threshold for the overall study population from the current U.S. conventional value of 20 μg/g to 15 μg/g would have resulted in 25 additional cancer cases detected (3% increase) and required evaluation of 11 308 additional positive test results (23% increase). Further research is needed to assess the cost-effectiveness of such changes and their practicality across settings with differing resources. Note: Dr. Selby had full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 1 year of follow-up substantially decreases the effect of repeated testing and gives an estimation of the proportion of cancer cases detected before the next recommended test. For this analysis, we used FIT sensitivity of the baseline test only, defined as the proportion of patients with a CRC diagnosis within 1 year of a positive baseline test result, regardless of the results of subsequent FITs, if performed. Likewise, we used specificity of the baseline test, defined as the proportion of patients without a CRC diagnosis within 1 year of a negative baseline test result. We also calculated the positive predictive value, the proportion of patients with a positive baseline FIT result who had a cancer diagnosis within 1 year.
Among 640 859 KPNC and KPSC members with a quantitative FIT result available from 2013 to 2014, 26 654 (4.2%) had a positive result at baseline and 790 (0.12%) received a CRC diagnosis during 1 year of follow-up. Of the 790 cancer cases, 297 (38%) were right-sided colon cancer (Appendix Table 4 ). Appendix Table 5 shows the distribution of FIT results among participants with cancer within 1 year. The distribution of results for those without cancer is shown in Table 2 . The values for those with cancer within 1 year were higher than for those with cancer within 2 years (Table 3) , indicating that a greater portion of cancer cases within 1 year were detected by the baseline FIT and not a subsequent FIT.
At the current positivity threshold of 20 μg/g, 614 of 790 patients with a cancer diagnosis had a positive baseline FIT result, for a sensitivity of 77.7% (CI, 74.7% to 80.6%) and a corresponding programmatic specificity of 95.9% (CI, 95.9% to 96.0%) (Appendix Table 6 ). Programmatic sensitivity increased to 75.1% (CI, 72.5% to 77.6%) at a threshold of 10 μg/g, again with significant increases in the number of positive results per cancer case detected (49 [CI, 46 to 53] to 80 [CI, 75 to 86]). In a comparison among age groups and between men and women, overall trends were similar for 2-and 1-year follow-up (Appendix Tables 6 and 7) . Specifically, at the current threshold of 20 μg/g, FIT sensitivity decreased with age, from 82.7% (CI, 77.8% to 87.0%) in persons aged 50 to 59 years to 76.8% (CI, 71.8% to 81.2%) in those aged 60 to 69 years and 71.5% (CI, 64.3% to 78.0%) in those aged 70 to 79 years (P = 0.016), and was lower in women than in men (73.8% [CI, 68.6% to 78.6%]) vs. 80.3% [CI, 76.5% to 83.8%]; P = 0.031).
Appendix Table 3 . * Values are micrograms of hemoglobin per gram of stool. † P < 0.001 for difference in fecal hemoglobin concentration between age, sex, and tumor location subgroup at this percentile. ‡ Results >200 μg/g are reported as greater than assay and here denoted >200 μg/g.
